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Abstract
Inflammation is a common defensive response that is activated after different harmful stimuli. This chronic, or pathological,
inflammation is also one of the causes of neoplastic transformation and cancer development. MAP17 is a small protein
localized to membranes with a restricted pattern of expression in adult tissues. However, its expression is common in
destabilized cells, as it is overexpressed both in inflammatory diseases and in cancer. MAP17 is overexpressed in most, if
not all, carcinomas and in many tumors of mesenchymal origin, and correlates with higher grade and poorly differentiated
tumors. This overexpression drives deep changes in cell homeostasis including increased oxidative stress, deregulation
of signaling pathways and increased growth rates. Importantly, MAP17 is associated in tumors with inflammatory cells
infiltration, not only in cancer but in various inflammatory diseases such as Barret’s esophagus, lupus, Crohn’s, psoriasis
and COPD. Furthermore, MAP17 also modifies the expression of genes connected to inflammation, showing a clear
induction of the inflammatory profile. Since MAP17 appears highly correlated with the infiltration of inflammatory
cells in cancer, is MAP17 overexpression an important cellular event connecting tumorigenesis and inflammation?
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Background
Inflammatory response is a common defensive process acti-
vated after different harmful stimuli, constituting a highly
complex biological mechanism. Through inflammation, the
clearance of damaged cells and the removal of pathogens
are allowed, initiating both healing and regenerative pro-
cesses [1, 2]. Macrophages and other inflammatory cells are
attracted and activated by signals generated because of the
inflammatory process, generating cytokines and proinflam-
matory chemokines that are released by these cells [3, 4].
As consequence, circulating leukocytes are attracted to the
site of inflammation. Once harmful agents have been
removed, inflammation also allows the activation of mecha-
nisms of tissue repair [5]. At that way, many cytokines can
activate regeneration-activating pathways such as those of
YAP, Notch and Stat, all of them involved also in the acqui-
sition of stem cell properties [6–8] . The inflammatory
process ends when the activated cells undergo apoptosis in
a highly regulated process that finishes after pathogens and
cell debris have been phagocytized [9]. Inflammation may
turn chronic if the inflammatory cells are not able to
eliminate the pathogen. If this happens, a high level of
leukocyte infiltration appears in damaged tissues. Many
syndromes with an inflammatory component can appear
due to this chronic inflammatory condition, like Crohn’s
disease, lupus, psoriasis and atherosclerosis [10, 11]. In
addition, it has also been connected to Alzheimer’s disease
and cardiovascular disease [11, 12].
This chronic, or pathological, inflammation has been
also connected to neoplastic transformation and cancer
development [13, 14]. At that way, around 25% of the
tumors have been highly connected with chronic inflam-
mation derived from an infection, especially stomach
cancer [15, 16]. Helicobacter pylori, that causes persistent
gastritis, increases the risk of developing gastric tumor up
to 75% [17]. In addition, the hepatitis B or C viruses
increase the risk of developing hepatocellular carcinoma
[18]. In addition, chronic inflammation in organs like pan-
creas or prostate is commonly followed by the appearance
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of tumors [19, 20]. Crohn’s disease increases the risk of
developing colorectal cancer by up to ten-fold [11]. As
consequence, all these tumors, with an important inflam-
matory component in its origin, are characterized by the
presence of immune cells and mediators of inflammation,
being able leukocytes to constitute up to 50% of the total
tumoral mass [21, 22]. Cancer cells and macrophages inter-
action stimulates the latter to produce proinflammatory
cytokines, like IL-8, attracting as consequence additional
inflammatory cells [4]. The subsequent inflammatory
microenvironment has been accepted as an essential
component of all tumors [21, 23]. Recent efforts have been
dedicated to understand the tumor-elicited inflammation,
an inflammatory reaction necessary for tumor development
and detected in many solid malignancies [24–28].
MAP17, also known as PDZK1IP1, DD96 or SPAP
[29–31], was identified as an upregulated gene in the
malignant epithelial cells of renal cell carcinomas [29]. It
was also identified in a genome-wide retroviral cDNA
screen designed to search for genes conferring selective
advantage to cells during tumorigenesis [32]. MAP17
expression is restricted to specific epithelial cell popula-
tions associated with the apical brush border, such as
the proximal tubular cells of the normal kidney, how-
ever, it has been shown to be a gene commonly upregu-
lated in tumors, being overexpressed in more than 50%
of the advanced tumors or metastases analyzed [31].
MAP17 is overexpressed in most human carcinomas
and in other non-epithelial neoplasias, such as glioblast-
omas or lymphomas [33, 34]. In addition, MAP17
overexpression is a common feature of tumors and is
associated with tumor progression, being correlated with
two of the most important events leading to a malignant
phenotype: cellular immortalization and transformation
[31, 35, 36]. Furthermore, we have recently shown that
high MAP17 expression is not restricted to cancer [37].
By its PDZ-binding domain, MAP17 acts as a carrier
from the Golgi to the cell membrane increasing protein
membrane loading and inducing the attraction of
inflammatory cells. Furthermore, MAP17 also modifies
the expression of genes connected to inflammation,
showing a clear induction of the inflammatory profile.
Thus, MAP17 expression regulates the expression of
inflammation-related genes, through induction of genes
like NFAT2 and IL-6. Therefore, the expression of
MAP17 triggers chronic inflammation not only in cancer
but in various inflammatory diseases such as Barret’s
esophagus, lupus, Crohn’s, psoriasis and COPD. Since
MAP17 appears highly correlated with the infiltration of
inflammatory cells in cancer, does MAP17 expression
triggers chronic inflammation in tumors? In the present
manuscript we will review the data about this gene and
its relevance in tumorigenesis and chronic inflammation,
and the essential role of MAP17 in both.
Main text
MAP17 overexpression increases tumorigenic potential
Due to the increased expression of MAP17 found in
advanced tumors and metastases, it is important to explore
the consequences of MAP17 expression in human cells. In
this way, most of the research done so far has been focused
on what occurs in cells with increased MAP17 expression.
Likewise, initial experiments using forced expression of
MAP17 in non-tumoral immortalized human mammary
epithelial cells (HMECs) showed a decrease in both cell
proliferation and tumor growth, and cells appeared to take
on a senescent morphology [34, 38]. This advanced stage of
differentiation, or senescence, has been shown to be related
to MAP17-induced increases in ROS. This effect seems to
be related to p38α phosphorylation because shRNA against
p38α was able to overcome the MAP17-induced senes-
cence and allowed for MAP17-dependent tumorigenesis of
immortalized HMECs [39].
Most of the research done so far concerning the role
of MAP17 in cancer has shown that MAP17 works as
an oncogene, increasing tumorigenicity when it is
overexpressed [31, 40–43]. In addition, MAP17 levels
are correlated with tumoral progression, being higher in
late-stage or metastatic tumors than in benign tumors or
normal tissues. MAP17 overexpression has been found
in the advanced stages of ovarian, cervical, laryngeal and
prostate cancer [31]. Likewise, a high percentage of
advanced tumors (50–90%) exhibit high levels of MAP17,
and this expression is correlated with an increase in cell
dedifferentiation [35, 36, 39].
Increased MAP17 levels have a marked effect on
tumor progression [31, 39–41]. Tumor cells lines with
low MAP17 always exhibit an increase of tumorigenic
properties due to MAP17 ectopic overexpression. Assays
with A375 melanoma cells showed that cells overex-
pressing MAP17 grew faster than control cells and thus
had a proliferative advantage [40]. Ectopic MAP17
expression induced an increase in the proportion of
holoclones, which can be related to an increase in stem
cell-like properties, as it has been previously described
[44–49]. In addition, soft agar and tumorsphere assays
also showed an increase in the number and size of
colonies formed compared to parental cells [39, 40].
Additionally, MAP17 overexpression in cancer cells
reduced the percentage of apoptotic cells and induced
an increased growth ratio in mouse tumors [39, 40].
On the other hand, MAP17 downregulation by shRNA,
both in MAP17-overexpressing cells, for example, in Calu3
or MDA-MB-431 cells, that naturally express high levels of
MAP17, reduced tumorigenic properties [39, 41]. Similarly,
a decrease in colony size and a reduced number of colonies
were observed due to MAP17 downregulation, indicating
that MAP17 expression is required to maintain increased
tumorigenic properties. Other experiments using siRNA
García-Heredia and Carnero Molecular Cancer  (2018) 17:80 Page 2 of 16
against MAP17 in thyroid cancer cell lines additionally
impaired cell migration and invasion [50]. The downregula-
tion of MAP17 also reduced the number and size of tumor-
spheres and of holoclones, indicating the MAP17-induced
regulation of the cancer stem cell pool [51].
Therefore, the overexpression of MAP17 increases the
cancer stem cell-like pool of tumor cells, independently
of the tumor origin of the cells, while the downregula-
tion of the protein in cells that endogenously expresses
it, triggers the reduction of this cancer stem cell pool
[51]. This feature has been related to the activation of
the Notch pathway as we will explore later. Importantly,
this feature may explain the increase in the tumorigenic
properties and the resistance to apoptosis observed in
tumor cells.
MAP17 and inflammation
Downregulation of SLC34A2, a Na+-dependent phosphate
transporter correlated with MAP17 expression [52], has
been associated with the initiation and progression of lung
adenocarcinoma through AKT/PI3K activation [53]. In this
study, MAP17 appeared to be correlated with complement
genes (C3, C4b, C5) and complement-associated genes
(FGA, FGB, FGG), suggesting possible activation of the
alternative complement pathway, an usual event in cancer
cells [54]. The complement system is associated with both
inflammatory diseases and cancer [55], showing that
MAP17 could have an important role not only in cancer
but also in inflammation. In this way, MAP17 was found to
be significantly overexpressed in patients with Crohn’s
disease and ulcerative colitis compared to its expression in
normal patients and caused significant changes in six
additional genes (CXCL1, MMP7, SLC6A14, SLC26A2,
REG4,VNN1) [56].
Although both studies pointed to a possible role of
MAP17 in inflammation, there were no data on what
that role could be. However, two studies have shown
that MAP17 can induce an inflammatory phenotype,
similar to the phenotype that occurs when MAP17
increases tumorigenic properties. The first study estab-
lished a relationship between MAP17 and filaggrin, a
cornified envelope-associated protein usually downregu-
lated in inflammatory skin diseases such as atopic
dermatitis [57]. In a meta-analysis of microarray studies
of four different dermatological diseases (dermatitis,
acne, nickel allergy and psoriasis), MAP17 expression
was correlated with a profile of cytokines (IFN-γ, IL-4,
IL-6, IL-17A, IL-17F, and IL-22) that induced transcrip-
tional downregulation of filaggrin [58]. Indeed, the
overexpression of the C-terminal, cytoplasmic fragment
of MAP17, from amino acid 59 to 114, in keratinocytes
decreased the expression of filaggrin [58]. Additionally,
keratinocyte treatment with IFN-γ, IL-4, IL-6, IL-17A or
IL-22 induced MAP17 expression, showing its connection
with the inflammatory response [59]. In inflammatory
diseases such as psoriasis or Crohn’s disease, cytokines are
secreted by T-helper cells [60, 61], and it is hypothesized
that MAP17 upregulation is a secondary effect of this
increased cytokine secretion. Like for epidermal diseases,
the higher amount of T-helper cells in tumors suggest that
MAP17 upregulation could also be the result of the upreg-
ulation of several cytokines [58]. Interestingly, the gene for
PDZK1, a known protein that interacts with MAP17 [62],
is localized within the atopic dermatitis-linked region on
human chromosome 1q21, such as the filaggrin gene [58].
In line with these data, in a recent study, we showed
that MAP17 directly regulates the expression of genes
related with the inflammatory response, such as HLAs,
IL-6 and NFAT2 [63–65]. Therefore, cells with high
MAP17 levels also exhibit increased cytokine (i.e., IL-6)
secretion, which induces differentiation of monocytes to
dendritic cells [37]. As such, an increased MAP17 level
is an important event both in cancer and in inflamma-
tory diseases, which makes it possible to design common
strategies that can treat both diseases similarly in cases
with MAP17 overexpression.
MAP17 gene
Human MAP17 is encoded on chromosome 1p33 in the
SCL/TAL1 locus, where TAL1, a basic HLH protein
essential in the production of the hematopoietic lineages,
and the 3′ sequence of STIL, are localized (Fig. 1a). In
addition, other genes coding for members of the
cytochrome P450 family (CYP4B1, CYP4A11), MCPH7,
CMPK1 and members of the forkhead family (FOXE3,
FOXD2) are also localized close to MAP17 gene [35].
STIL, TAL1 and MAP17 genes constitute a genomic
region of approximately 88 kb with multiple regulatory
elements, both enhancers and repressors [66]. MAP17
shares some regulatory elements with TAL1, and the ex-
pression of both genes is correlated in all hematopoietic
cell types where TAL1 is expressed. In fact, MAP17 is
immediately positioned at the 3′ end of the hematopoietic
master regulator TAL1 [67, 68]. Deletion of this enhancer,
which is evolutionary conserved, reduced both TAL1 and
MAP17 expression [69, 70]. In addition, MAP17 upregula-
tion has been detected during megakaryocyte differenti-
ation from CD34+ hematopoietic progenitor cells [71].
The SCL/TAL1 locus is also regulated through histone
acetylation, and one of these acetylation sites is localized
over the MAP17 promoter. This modification, found in
renal tubule cells with high MAP17 levels, could be
related with active transcription of this gene [67]. Two
non-coding RNAs, named ncRNA-a3 and ncRNA-a4, have
been detected close to MAP17 gene in the SCL/TAL1
locus, although a possible effect on MAP17 expression
remains to be characterized [72].
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However, it has also been shown through bioinformatics
analysis that TAL1 and MAP17, although correlated, do
not share strong network connections during erythroid
differentiation, suggesting they may have independent
functions [73]. In fact, MAP17 expression in tumors is not
correlated with TAL1 expression. While MAP17 levels are
typically increased in tumor samples compared to levels in
non-tumoral samples, no changes in the expression of
TAL1 have been observed, showing that, at least in cancer
cells, MAP17 transcription is independent [31].
The MAP17 gene itself is divided into four different
exons that together generate a 600 bp transcript (Fig. 1b).
Up to now, only two different mutations have been de-
scribed affecting this gene. One of them, C403T, was identi-
fied in malignant pleural mesothelioma tumors and causes
an amino acid substitution, T79I, in the C-terminal cyto-
plasmic region [74]. The second identified mutation, C176
+ 1G >A, is in the boundary between exon 2 and intron 2
and causes a shift of the reading frame in such a way that
activation of SGLT2, a protein related with MAP17, is no
longer possible [75]. This mutation turned MAP17 into a
non-functional protein and caused loss of the phenotype
typically observed when the wild-type gene is expressed.
However, MAP17 expression in tumors usually increases
due to progressive demethylation and/or oncogenic activa-
tion of the promoter [29, 31]. Both effects cause an increase
in protein expression, mostly through mRNA amplification
[31, 34]. It has been shown that MAP17 is differentially
upregulated in distant metastases [30].
MAP17 protein
MAP17 is a small, non-glycosylated protein of approxi-
mately 17 kDa usually localized to the plasma membrane of
cells and is associated with areas of cell-cell contact [34].
Although its structure is not known, it has a double hydro-
phobic region that allows it to function as an anchored
membrane protein [38, 76]. It seems to form homodimers
of 24 kDa, probably through a disulfide bond between
intracellular Cys55 residues [77]. No functions have been
reported for the N-terminal domain, with the exception of
a potential signal peptide for its localization [29]. MAP17
functionality is localized to its C-terminal sequence, which
contains a PDZ-binding domain composed of the last four
amino acids (STPM) that allows its interaction with several
PDZ domain-containing proteins (Fig. 1c) [35, 38, 76, 78].
In addition, the MAP17 PDZ-binding domain is essential
to increase cell growth rate, clonability, growth in soft agar
and tumorspheres size and/or number [40, 41].
Although the function(s) of MAP17 have not been fully
determined yet, it has been postulated that its primary role
is to act as a cargo protein, allowing the movement of pro-
teins from the Golgi apparatus to the plasma membrane
[32, 41, 76, 77]. The PDZ-binding domain of the MAP17 C-
Fig. 1 a Schematic representation of the SCL/TAL1 locus in chromosome 1p33, showing the positions of STIL, TAL1 and MAP17 genes, as well as
the regulatory regions. b MAP17 gene, composed by 4 different exons. c MAP17 protein, showing the transmembrane domains, the PDZ-binding
domain (white), and the interaction region with NUMB (orange)
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terminal region allows for the configuration of a complex
network of protein interactions that will be discussed below.
In normal human cells, its expression is restricted to
specific epithelial cells from the kidney (proximal tubular
cells), epidermal keratinocytes and the spermatids of the
seminiferous tubules [34, 38]. In addition, it has also
been detected in the kidney, lung and liver of adult
mouse tissues and in the proximal tubules of the kidney
cortex and the spermatids of the seminiferous tubules of
rats [77]. It has also been shown to be correlated with
PDZK1 [79].
MAP17 and PDZK1: An interaction that allows for the
construction of a variable complex
One of the first proteins described to interact with
MAP17 was PDZK1 [62, 78, 79]. MAP17-PDZK1 inter-
action occurs between the STPM sequence of MAP17 and
one of the PDZ-binding domains of PDZK1. In this way,
MAP17 interaction with PDZK1 and other proteins, such
as NaPiIIa and NHE3, is disrupted by the deletion of the
STPM sequence from MAP17 [39, 76, 79]. All published
data about MAP17 in non-tumor cells point to its role as
a membrane protein anchoring the PDZK1 protein.
Similarly, it has been described that MAP17 overexpres-
sion in a transgenic mouse model caused PDZK1-induced
liver deficiency, suggesting that MAP17 could act as an
endogenous regulator of PDZK1 turnover in situations of
increased degradation of PDZK1 and higher HDL plasma
levels [79]. MAP17 together with PDZK1 and MRP2
(multidrug resistance-associated protein 2, also called
cMOAT or ABCC2) may constitute a heteromultimeric
protein complex [62]. These proteins together may have
an important role in multidrug resistance because proteins
with PDZ domains, such as PDZK1, are involved in
recruiting membrane-associated proteins that are involved
in many different signaling pathways [35].
PDZK1 belongs to the NHERF (sodium hydrogen
exchange regulatory factor) family, which comprises
PDZ domain-containing proteins with important roles in
cell function regulation. This family is constituted by
four members, NHERF1, NHERF2, PDZK1 (NHERF3)
and IKEPP (NHERF4), with similar homology domains
[80], although NHERF1 and NHERF2 have 2 PDZ
domains, while PDZK1 and IKEPP have 4 PDZ domains
[81]. Proteins of this family are mostly expressed on the
apical side of polarized epithelial cells, mainly from the
kidney, small intestine and liver [82, 83]. These proteins
can regulate the functional activity and expression of cell
surface transporters, most of which are part of the ABC
family [81]. Other important elements, such as signaling
proteins, hormone receptors and cytoskeleton structural
elements, also interact with NHERF proteins [80, 84].
Regarding individual members of NHERF family, it has
been shown that NHERF1 and NHERF2 are important
in inhibiting the Na+-H+ exchange isoform 3 (NHE3).
PDZK1 is a scaffolding protein that allows for the
assembly of several proteins into functional complexes
and is a critical regulator of intracellular signaling in
response to specific stimuli [81]. PDZK1 and NHERF1
can form hetero-oligomers that likely allow for the
formation of an entire network of PDZ adapter proteins
beneath the plasma membrane [85]. Similarly, PDZK1
regulates the solute carriers SLC9A3 (sodium/hydrogen
exchanger, NHE3) [86], SLC15A1 (oligopeptide trans-
porter, PEPT1) and SLC22A5 (carnitine/organic cation
transporter, OCTN2) in the small intestine [87] and reg-
ulates the cystic fibrosis transmembrane conductance
regulator (CFTR) [88] and the anion exchangers of the
SLC26A family, leading to PDZK1 stabilization. The
binding of CFTR to DRA and PAT1 results in activation
of the Cl−/HCO3
− exchanger. In addition, PDZK1 also
interacts with AKAP10, FARP2, sodium-hydrogen anti-
porter 3 regulator 1, SLC22A12, SLK, SLC22A4, CLCN3,
and SLC34A3 [89]. In this way, PDZK1 can regulate the
activity of cation and anion transporters, modifying cell
membrane properties according to cellular needs.
The described interaction of MAP17 with PDZK1 allows
for its function as an atypical anchoring site for PDZK1 and
other NHERF proteins, and allows for MAP17 interaction
with the NaPi-IIa/PDZK1 protein complex in renal prox-
imal tubular cells [78]. In this way, MAP17 overexpression
in opossum kidney cells, together with PDZK1 and IKEPP,
allows for internalization of NaPiIIa from the apical mem-
brane into the trans-Golgi network [76, 78]. The complex
composed of MAP17, NHERF1 and PDZK1 may alter the
membrane localization of pumps and transporters and thus
deregulate the intracellular and extracellular cation/anion
equilibrium [35]. In spite of the described PDZK1-MAP17
interaction, PDZK1 downregulation had no effect on
MAP17 expression nor in its cellular distribution [90].
These results suggest that PDZK1 is not required for the
membrane localization of MAP17.
MAP17 influences glucose/mannose uptake by SGLT1/2
regulation
MAP17 overexpression has also been shown to stimulate
specific Na+-dependent transport of mannose and glucose
in Xenopus oocytes and mammary cells [32, 77]. In this
way, it has been shown that this protein modifies the
activity of SGLT1 and SGLT2 (Na+-dependent glucose
transporters 1 and 2) [36, 75]. These transporters are
mediators of apical glucose uptake in intestinal cells.
When coupled to the Na+/K+ ATPase to provide the
necessary energy, GLUT1, a glucose transporter, facilitates
the diffusion of intracellular glucose from the basolateral
membrane to the bloodstream [91]. In this way, glucose is
efficiently transported from the lumen of the small
intestine to the blood.
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Although SGLT1 and SGLT2 do not have PDZ domains
nor PDZ-binding domains, their activities are modulated
by MAP17/PDZK1 expression, suggesting that other
factors may be involved. MAP17 has been identified as a
factor stimulating the uptake of α-methyl-glucose, a non-
metabolizable glucose analog, by SGLT2, increasing its
ability to transport glucose [75]. In fact, MARDI protein,
which shares a common amino acid sequence with
MAP17 within its two transmembrane domains, can also
stimulate SGLT2 [75]. Given that the addition of glucose
activates PDZK1-mediated Na+/HCO3
− cotransport [92, 93]
and that the activity of SGLT2 is potentiated by MAP17
[75], SGLT2, MAP17 and PDZK1 could be part of a
signaling complex. Although SGLT1 activity is not directly
dependent of MAP17, both proteins appear to be linked in
cervical cancers. In line with this, glucose uptake was
increased an average of 4-fold in cells overexpressing
MAP17, an effect which could be inhibited by treatment
with the SGLT inhibitor phloridzin [36]. In addition, a
significant positive correlation between SGLT1 and MAP17
was found in different cancers [36].
PDZK1 and SGLT1/2 appear to be connected given the
described function of PDZK1 as a platform for ion trans-
porters and the connection of SGLT1/2 with the transport
of glucose in a sodium-dependent manner [36, 75]. In
addition, the ability of MAP17 to modify the localization
of ion transporters identifies it as a regulatory protein for
ion and glucose transport, which it accomplishes by com-
petitively binding to PDZ-binding domains to alter the
stoichiometry of the transporter-PDZ proteins [77, 94].
MAP17 overexpression modifies cell signaling pathways
Changes in the tumorigenic properties of cells overex-
pressing MAP17 suggest that these cells likely have
modifications in their signaling pathways. Research done
so far has shown that MAP17 overexpression causes a
pleiotropic effect, modifying several signaling pathways.
Here, we describe the effects on different signaling path-
ways induced by MAP17 overexpression.
MAP17 overexpression allows for activation of the notch
pathway
Aberrant activation of the Notch signaling pathway has
been reported both in cancer cells and in tumors and is
correlated with increased stem-like properties in tumor
cells and with cancer metastasis [41, 95, 96]. Notch
protein, which is localized to the plasma membrane in
its inactive state, interacts with ligand receptors on
neighboring cells and is then proteolytically processed
by γ-secretase. As a consequence of this processing, the
Notch intracellular domain (NICD) is released into the
cytoplasm, resulting in the active form of Notch.
Translocation of the NICD to the nucleus allows for the
transcription of Notch target genes, including genes
from the HES and HEY families [97, 98]. The Notch
pathway is negatively regulated by NUMB, which
interacts with the NICD in such a way to interfere with
its nuclear translocation and to allow for the ubiquitination
of the NICD prior to its proteasomal degradation [99–101].
As such, it has been shown that lower NUMB levels are
correlated with increased Notch signaling and increased
tumorigenic properties [102, 103]. In addition, tumors with
decreased NUMB levels are correlated with a worse prog-
nosis and a more dedifferentiated state [103–105], sharing
features with tumors expressing MAP17.
MAP17 overexpression activates the Notch pathway
due to the direct interaction between MAP17 and NUMB
in tumor cells [41]. Because this interaction is mediated by
the last 13 amino acids of MAP17, deletion of this region
(tMAP17, truncated MAP17) blocked the interaction of
MAP17 with NUMB and resulted in a loss of MAP17-
induced tumor-promoting properties. In this way, cells
overexpressing tMAP17 behaved such as control cells.
Consistent with this, both MAP17 overexpression and
NUMB downregulation by specific shRNA caused similar
effects, with an increase in nuclear NICD and an increase
in the expression of Notch-related genes, including HES1
and HES5 [41, 106]. In addition, stem-cell related genes
and cell surface markers, including OCT4, NANOG,
SOX9, KLF4, CD44 and CD133, were upregulated in both
conditions, suggesting an increase in stem-cell properties
in cells, which was confirmed by tumorspheres and clonal
growth assays. In addition, analysis of human cancer data-
sets confirmed that MAP17 correlated with genes from
Notch pathway.
These experiments show that one of the main effects
driving the oncogenic effect of MAP17 is its interaction
with NUMB, which allows for aberrant activation of the
Notch pathway. However, MAP17 overexpression is also
related with other pro-oncogenic effects.
MAP17 overexpression inhibits NFκB pathway
In addition to its effect on Notch signaling, it has been
shown that MAP17 overexpression reduces NFκB activa-
tion and cell autophagy [32]. NFκB is known to activate
antiapoptotic genes and promote cell survival, and the
NFκB pathway has been described as an important survival
mechanism in tumor cells [107]. MAP17 prevents the cyto-
protective activation of NFκB and cell autophagy induced
by bortezomib (velcade, PS-341) [42, 43]. Cells with higher
MAP17 expression levels showed decreased phosphoryl-
ation of NFκB, with a reduced nuclear accumulation of
NFκB-p65, lower IκBα levels, and lower levels of autophagy,
suggesting the high relevance of these two pathways in
MAP17-induced drug sensitivity [42, 43]. Cells overexpress-
ing MAP17 also showed decreased ERK1/2 phosphoryl-
ation levels at lower bortezomib concentrations [43].
Bortezomib also induces autophagy, a process characterized
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by the intracellular formation of the autophagosome, a
double-membrane vesicle in which cellular components are
digested and recycled [108, 109]. Cells overexpressing
MAP17 reduced bortezomib-induced autophagy [43].
Tumor necrosis factor (TNF) is one of the most import-
ant cytokines with a wide range of roles (from DNA
fragmentation to NFκB phosphorylation), being bypassed
by MAP17 overexpression. In this way, MAP17 blocks
TNF-induced growth arrest by inhibiting p21 activation
and pRB dephosphorylation. TNF inhibition due to MAP17
expression is specific, because MAP17 does not alter the
response of other cytokines, such as IFN-γ [32].
Fibroblasts expressing c-Myc enter apoptosis under low
serum conditions [110]. However, MAP17 overexpression
reduced the percentage of cells expressing c-Myc that
entered apoptosis, with a reduction in caspase-3 activity of
up to 60% [33]. The protective effect exerted by MAP17 is
due to the activation of the AKT/PI3K pathway because
cells overexpressing MAP17 were insensitive to serum
starvation and showed no AKT dephosphorylation, which
promoted cell survival [33].
MAP17 overexpression increases reactive oxygen species
production
Reactive oxygen species (ROS), such as superoxide (O2
−),
hydroxyl radicals (OH−) and hydrogen peroxide (H2O2),
are considered to be by-products of the mitochondrial
electron transport chain [111]. Under physiological condi-
tions, antioxidant enzymes, such as superoxide dismutase,
catalase, and others, exist in a delicate balance with these
oxidative inputs, protecting cells from the oxidative stress
induced by ROS [112]. It has been described that moder-
ate to high levels of ROS promote cell proliferation,
survival and migration [113, 114]. However, altered ROS
levels promote various pathological conditions, including
cancer. ROS-induced oncogenic effects include changes in
gene expression regulation, increased mutagenic rates and
genomic instability [39, 114]. After oncogenic transform-
ation, cells rapidly activate a stress response as a protective
measure to overcome oncogene-induced cell death and
senescence [115].
Although ROS increase is a typical feature of cancer cells
and is partially responsible of the enhanced malignant
properties of tumor cells, it is also a potent proapoptotic
stimulus [42, 116]. ROS generation in tumors, and the sub-
sequent oxidative stress, actually occurs at sublethal levels
[117], making it easier to reach levels causing cell death
[35, 118]. Therefore, although many cancer cells can toler-
ate limited doses of ROS, excessive intracellular ROS accu-
mulation overruns detoxification enzymes, and apoptosis is
initiated [119]. Thus, patients with tumors expressing high
ROS levels could benefit from therapies increasing oxida-
tive stress. However, antioxidants and low ROS levels that
induce antioxidant defenses both appear to benefit tumor
growth and could enhance anticancer therapy resistance
[120]. As such, understanding the duality of ROS as cyto-
toxic molecules and key mediators in signaling cascades
may provide novel opportunities to improve cancer thera-
peutic interventions [121].
Mitochondrial defects in oxidative phosphorylation
(OXPHOS), which are typical of tumor cells, cause reduced
ATP production, with most of the increases in ROS being
due to the electron transport chain inhibition because of
OXPHOS defects [122]. Lower ATP levels force tumor cells
to have a high rate of glycolysis, supported by an increase
in glucose uptake usually 20–30-fold higher in tumor than
in normal cells [123]. This enhancement in glucose uptake
occurs via GLUT1 and SGLT1 activation [123]. As a conse-
quence of increased glycolysis, tumor cells accumulate
lactate, which affects them negatively through changes in
intracellular pH [124, 125]. This effect forces the cells to
regulate their intracellular pH to survive, enhancing the
expression of membrane-localized transporters and
exchangers. Some of these membrane transporters are
regulated by MAP17 levels and are normally localized by
NHERF proteins binding [35, 126, 127].
Although MAP17 has no enzymatic activity, its overex-
pression causes an increase of 30–40% in ROS generation
levels, compared to control cells [35, 39, 40]. In fact,
MAP17 overexpression alters the mRNA levels of genes
regulating oxidative stress [36, 43]. Because MAP17 effects
SGLT1/2 to enhance glucose and mannose uptake, glycoly-
sis is activated, and ROS levels are increased as a by-
product [36, 75, 77]. In addition, changes in the MAP17-
PDZK1 interaction could also alter the intracellular and
extracellular ion balance, thus modifying the intracellular
redox balance [35, 40]. As such, the increased ROS levels
induced by MAP17 overexpression are partially responsible
for the enhanced tumorigenic properties of cancer cells
overexpressing MAP17 and for the previously described
modified cellular pathways [35, 40]. It is interesting to note
that MAP17 without its PDZ-binding domain is unable to
increase tumorigenic properties and unable to increase
ROS production [40].
High ROS levels activates the AKT/PI3K pathway by
direct oxidation and inactivation of PTEN and other AKT
phosphatases, thus maintaining AKT activation even in
the absence of a PI3K signal [33]. PTEN is responsible for
AKT dephosphorylation and is inactivated by oxidation
under ROS stress [128, 129]. The levels of oxidized PTEN
in MAP17-overexpressing cells under serum deprivation
conditions that potentiate ROS production was up to 10-
fold higher than in control cells, indicating that the AKT/
PI3K pathway remains activated [33]. Under the same
serum deprivation conditions, treatment of MAP17-
overexpressing cells with antioxidants prevented the acti-
vation of AKT and restored the level of apoptosis [33].
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Inactivation of p38α looks to be an essential step due to
its role as a sensor for ROS levels, and these levels can
simultaneously act as a switch for the tumorigenic and
suppressive actions of p38α [130–132]. As it was stated
above, active, phosphorylated p38α in non-tumor cells
blocks the tumorigenic transformation induced by
MAP17. Both the inactivation of p38α and its downregu-
lation by shRNA caused faster growth and higher colony
numbers in cells overexpressing MAP17 [39]. AKT
pathway activation by MAP17 expression may lead to
diminished p38α phosphorylation, probably through the
activation of kinases upstream of p38, such as ASK1 or
MEKK3. Most likely, ROS production due to MAP17
overexpression results in the oxidation of certain cysteine
residues of thioredoxin, which induces the dissociation of
p38α from ASK1, a kinase involved in p38α activation.
Thus, prior p38α inactivation is necessary for the higher
ROS levels and increased tumorigenic properties caused
by MAP17. This makes cells with no p38α more suscep-
tible to MAP17 oncogenic alteration [39].
It has been shown that cells with high MAP17 levels are
more sensitive to treatments that increase ROS produc-
tion, likely because the increased ROS can tip the balance
towards apoptosis. As such, the combination of MAP17
overexpression with antioxidants in rat fibroblasts
overexpressing c-Myc reduced the survival of MAP17-
expressing clones, suggesting that ROS generation acts as
a mediator of MAP17-induced survival through PI3K/
AKT signaling [33]. In cells overexpressing MAP17, anti-
oxidants reduced the oncogenic properties of MAP17,
decreasing both the number and size of colonies of
MAP17-expressing cells [40]. In addition, treatment of
non-tumor cells overexpressing MAP17 with antioxidants
reduced the occurrence of senescent cells [39]. These
findings showcase MAP17 expression as an interesting
biomarker for predicting prognosis and treatment design.
MAP17 as a biomarker for prognosis
Although the expression of MAP17 can be detected in all
tumor types, epithelial tumors showed a higher percentage
of tumors with high MAP17 expression levels (Fig. 2). In
some cases, as in pancreatic adenocarcinoma, the high
percentage of tumors with MAP17 overexpression could be
due to the late stage identification and analysis of the sam-
ples. Therefore, MAP17 is overexpressed in a great variety
of human carcinomas. Immunohistochemical analysis of
MAP17 during prostate, breast, and ovarian carcinoma pro-
gression shows that overexpression of the protein strongly
correlates with tumoral progression [31, 36, 39]. Many
tumor samples and tumor cells also express MAP17, and its
expression does not correlate with expression of SCL, the
neighbor gene reported to be co-expressed in some
hematopoietic cell lines [31]. SCL is also not expressed in
most MAP17-positive tumors, indicating the independent
transcription of MAP17, at least in carcinomas [31]. We
cloned the 5′ sequence of MAP17 and determined the min-
imal promoter sequence necessary to produce independent
activation of MAP17 [31]. Moreover, we have found that
the MAP17 promoter is activated by oncogenes [29, 31].
Fig. 2 Levels of MAP17 (PDZK1IP1) mRNA expression in different tumor types. Data obtained from cBioPortal. 1: Uveal melanoma; 2: Melanoma;
3: PCPG; 4: Thymoma; 5: Testicular germ cell; 6: Glioma; 7: Sarcoma; 8: DLBC; 9: AML; 10: GBM; 11: ACC; 12: Uterine CS; 13: Bladder; 14: Liver; 15:
Prostate; 16: Lung squamous; 17: Breast; 18: Uterine; 19: Thyroid; 20: Ovarian; 21: Lung adenocarcinoma; 22; Mesotheolioma; 23: Colorectal; 24:
Head & neck; 25: Cervical; 26: Cholangiocarcinoma; 27: Pancreas
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Taken together, these findings suggest that there is inde-
pendent activation of the MAP17 promoter that can be
driven by oncogenes, which might explain the common
overexpression of MAP17 in human carcinomas. However,
MAP17 is strongly demethylated during tumor growth and
might contribute to tumor growth in thyroid cancer [133].
We analyzed the expression of MAP17 in sarcomas and
its relationship with clinicopathological features [42]. We
found that the levels of MAP17 were related to clinical fea-
tures and poor survival in a cohort of patients with different
sarcoma types, and MAP17 expression was not restricted
to any specific tumor subtype [42]. MAP17 expression is
associated with poor overall survival and worse disease-free
survival. However, MAP17 and SGLT1 were expressed in
approximately 70% and 50% of cervical tumors of different
types, respectively, but they were not expressed in adenoma
tumors [36]. Furthermore, there was a significant correl-
ation between MAP17 and SGLT1 expression levels. High
levels of either MAP17 or SGLT1 correlated with improved
patient survival after treatment [36]. However, the patients
with high levels of both MAP17 and SGLT1 survived
through the end of the study. Therefore, the combination
of high MAP17 and SGLT1 levels is a marker for good
prognosis in patients with cervical tumors after cisplatin
plus radiotherapy treatment [36]. In larynx cancer, MAP17
expression is associated with better overall survival and
laryngoesophageal dysfunction-free survival. Locoregional
control in patients with high MAP17 showed better out-
comes than those with low MAP17 [134]. In addition, a
positive correlation was observed between MAP17 expres-
sion and SGLT1, and the combination of high levels of
MAP17 and SGLT1 also led to increased overall survival
[31, 134]. These findings suggest that MAP17, alone or in
combination with SGLT1, may become a novel predictive
biomarker for laryngeal carcinoma, another tumor with
similar therapeutic options, and for response to platins and
radiotherapy. In a follow-up study, patients with larynx
cancer were evaluated to determine whether γH2AX
phosphorylation (pH2AX), a component of the histone
octamer in nucleosomes which is phosphorylated upon
DNA damage, alone or in combination with the membrane
protein MAP17 could be used as a prognostic biomarker
[135]. The authors found that the dose of cisplatin but not
the length of radiotherapy influenced LDS. High-pH2AX
expression was associated with prolonged LDS while
MAP17 correlated with overall survival (OS). High-MAP17
and high-pH2AX combined analysis showed improved
LDS (with 61.35 months vs 32.2 months) and OS (with 66.
6 months vs 39.8 months). Furthermore, the subgroup of
patients with high-pH2AX and an optimal dose of cisplatin
was also associated with OS (72 months vs 38.6 months)
and LDS (66.9 months vs 27 months). These findings
suggest that pH2AX alone or in combination with MAP17
may become a novel and valuable prognostic biomarker for
patients with laryngeal carcinoma treated with preservation
approaches.
MAP17 guided therapeutic intervention
As we stated above, MAP17 expression correlates with
higher tumor grade and poorer differentiation. This can
be used as a tool to treat tumors with a poor prognosis
[36, 121, 134].
To explore the role of MAP17 as a predictive biomarker
of response to antitumor treatments, we performed a
search for MAP17 partners to identify a functional relation-
ship between MAP17 and a cellular process suitable for tar-
geting. In this search, we identified 184 proteins, most of
which belong to the proteasomal degradation pathway.
Because the inhibition of proteasomal function has been
described as a suitable antitumor strategy for some cancers,
we tested whether interfering with proteasomal function
might constitute a valuable therapeutic strategy in MAP17-
expressing cells. Bortezomib inhibits 20S proteasome func-
tion and possesses potent antitumor activity both in vitro
and in xenograft models of different tumors [136–138].
Bortezomib induces the unfolded protein response (UPR),
which is activated in response to alterations in the ER
physiological environment, and induces ROS production
[139, 140]. We found that cells overexpressing MAP17 are
more sensitive to bortezomib, and patients with higher
MAP17 mRNA levels respond better to this therapy and
exhibit prolonged survival [43]. We also showed that
MAP17 determines the bortezomib sensitivity by inhibiting
the cytoprotective effects related to bortezomib-induced
NFκB nuclear translocation and autophagy. Furthermore,
inhibition of oxidative stress abolishes the sensitivity to
bortezomib induced by MAP17 [43]. In tumors with high
MAP17 levels, this protein could functionally act as an
autophagy inhibitor, removing the need for synergistic
treatment with an autophagy inhibitor in cancer treatment.
This has a clear beneficial effect: reduced toxicity in
patients due to the restricted expression of MAP17 in
normal tissues. As such, no other secondary effects are
expected to arise due to treatment [43].
Therefore, high levels of MAP17 could be used as a
prognostic marker to predict the response of patients
with diseases that can be clinically treated with bortezo-
mib. Additionally, high MAP17 levels might be used to
select some patients with other tumors for which borte-
zomib are not currently indicated, such as breast cancer.
Sarcomas constitute a rare type of mesenchymal tumor
with a high rate of mortality in children and young adults
[141]. These tumors include approximately 60 different
subtypes and more than 50 types of benign tumors [142,
143]. This heterogeneous group of tumors exhibits differ-
ent MAP17 expression levels, and the expression of this
protein was correlated with response to bortezomib in a
panel of sarcoma cell lines [42]. In addition, forced
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expression of MAP17 in AA and AW sarcoma cells with
low MAP17 levels makes these cells more sensitive to bor-
tezomib treatment. However, downregulation of MAP17
expression by specific shRNA in sarcoma cell lines with
higher MAP17 levels showed a diminished sensitivity to
bortezomib treatment [42]. These results are also true for
patient-derived xenografts (PDXs), showing that the
bortezomib sensitivity of these tumors implanted in mice
was based on MAP17 levels [42].
Interestingly, the finding that MAP17 is associated
with a variety of inflammatory diseases such as Crohn’s
disease, COPD and psoriasis provides an avenue to test
bortezomib as an effective inhibitor of these chronic
inflammatory diseases.
On the other hand, cells overexpressing MAP17 were
shown to be more sensitive to treatment with cisplatin,
oxaliplatin or gemcitabine [36]. Additionally, tumor cells
overexpressing MAP17 were shown to be more sensitive
to radiation, and this sensitivity disappeared with antioxi-
dant treatment [134]. The variable sensitivity of cells to
different drugs based on differing MAP17 levels makes it
possible to use MAP17 expression levels as a marker of
response to therapies inducing oxidative stress. MAP17
expression is associated with an SGLT-dependent ROS
increase that acts as a second messenger, enhancing
tumorigenesis. While a mild increase in ROS has been
shown to activate signaling cascades that upregulate
tumorigenic processes, further ROS increases lead to a
potentially toxic cellular environment and thus pro-
grammed cell death [38]. The hypothesis is that tumors ex-
pressing both high levels of ROS and MAP17 proteins can
benefit from therapies such as cisplatin or radiotherapy that
Fig. 3 MAP17 function in normal cells. MAP17 interaction with PDZK1 allows the assembly of a multimeric and variable complex responsible
for cation/anion transport across the membrane. This complex potentiates the uptake of glucose by SGLT1/2 and the subsequent transport of
glucose by GLUT1 from basolateral membrane to the bloodstream. Presence of MAP17-PDZK1 complexes in the trans-Golgi network allows cells
to adapt to a change in ion transport requirements. The Notch pathway remains inactivated due to NUMB-NICD interaction, which labels NICD
for ubiquitination and degradation
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further increase oxidative stress as this could sensitize them
to cell death. In a cohort of patients with larynx cancer,
MAP17 expression was associated with overall survival and
laryngoesophageal dysfunction-free survival. Locoregional
control in patients with high MAP17 showed better
outcomes than those with low MAP17. These results are
consistent with what others have presented in cervical
cancer, in which high levels of MAP17 correlated with
improved patient survival after treatment [36] . Further-
more, proof of principle experiments in vitro demonstrated
that antioxidant treatments reduced the sensitivity of
MAP17-expressing HeLa cells to a value similar to parental
cells, confirming the relevance of the oxidative status of the
tumors in their response to radiation [36, 134]. In addition,
patients with high MAP17 and p-γH2AX, had better prog-
nosis after therapy with cisplatin [135]. Our published data
show that high levels of pH2AX correlate with better prog-
nosis after treatment with DNA-damage agents such as
cisplatin and radiotherapy, especially if cisplatin is given at
optimal doses. These data are suggestive of DNA Damage
Response (DDR) pathway activation, perhaps as an indica-
tor of low DNA-repair ability in response to DNA-
damaging agents in tumor therapy. The fact that doses of
cisplatin are important for survival seems to confirm this
hypothesis. In line with this, wild-type P53 with high levels
of pH2AX confers a good prognosis [135], suggesting that
P53 activity is essential to drive the physiological response
of apoptosis (or senescence) to DNA-damage agents in
tumors with DDR activated. Therefore, high levels of
MAP17 induced ROS that in turn increases DNA-damage
and DDR signaling. Upon further DNA-damage and
further increase in ROS as induced by cisplatin and radio-
therapy treatment, tumors with higher oxidative stress
(higher MAP17 and higher ROS as denoted by higher
pH2AX) are more suitable to undergo apoptosis in the
presence of P53 activity [144].
Fig. 4 Pathway alterations induced by MAP17 overexpression. MAP17 overexpression causes an increase in glucose uptake and Notch pathway
activation. NUMB interaction with MAP17 allows for activation of the Notch pathway, while the increased glucose uptake together with the
OXPHOS imbalance drives increased ROS production, changes to glycolytic metabolism, and activation of the AKT/PI3K pathway
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Finally, phloridzin, an inhibitor of the Na+-glucose
transporter, or furosemide, an inhibitor of the Na+-K+-
2Cl− symporter that reduces the reabsorption of NaCl
and decreases the positive potential derived from K+
recycling, have been tested in cells with high MAP17
levels [36, 40, 75]. Phloridzin acts on SGLT1 and SGLT2,
and due to the described effect of MAP17 on SGLT2, it
has been hypothesized that ROS production due to
MAP17 occurs through SGLT2 activation [75]. Previous
studies demonstrated that activation of SGLT1 rescued
enterocytes from apoptosis by activating PI3K [145] and
that inhibition of this membrane transport with
phloridzin also inhibited MAP17-dependent ROS
increase and cell proliferation [40].
Conclusions
All data currently existing about the role of MAP17
allow us to visualize two different regulation scenarios:
the first about the role of this protein in normal cells
(Fig. 3) and the other showing all the changes that occur
due to MAP17 overexpression (Fig. 4). At the latter case,
MAP17 is directly responsible for the activation of the
Notch pathway due to its described interaction with
NUMB and for disruption of glucose homeostasis due to
its effects on the SGLT proteins. The interaction of
MAP17 with SGLT proteins can increase glycolysis and
ROS production, allowing for the activation of the AKT/
PI3K signaling pathway.
MAP17 overexpression has been shown to be an im-
portant event triggering inflammation and increased
tumorigenic properties. Given its roles in modifying sig-
naling pathways and increasing ROS levels, MAP17 rep-
resents an important target for the design of specific
treatments. However, the lack of an enzymatic activity
by MAP17 necessitates the use of treatments that target
its interactions, such as those that disrupt MAP17-
PDZK1 or MAP17-NUMB binding (Table 1). These
strategies could be used to avoid both ROS increase and
the activation of stem cell-like genes, which could be es-
pecially useful in inflammatory diseases with confirmed
high MAP17 levels. However, in tumors, the higher ROS
levels due to MAP17 overexpression require treatments
that produce a subsequent ROS increase, enough to trig-
ger apoptosis in cancer cells (Table 1). Although the
small fraction already known has shown its pleiotropic
effects, more research is needed to completely unveil the
importance of MAP17 in cell homeostasis.
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Table 1 Observed effects due to MAP17 high expression in different cell lines and tumor types
Concurring factors Tumor/ cell type Effect Treatment Ref.
SGLT1 upregulation Cervical, laryngeal Better survival Cisplatin + radiotherapy; Phloridzin, in vitro [36, 133]
γH2AX phosphorylation Laryngeal Better survival Cisplatin + radiotherapy [134]
ND Sarcoma Poor survival Cisplatin, oxaliplatin, gemcitabine, radiation [38, 133]
ND Breast N.D. Bortezomib, in vitro [31, 36, 39, 43]
ND Prostate N.D. N.D. [31, 36, 39]
SGLT2 increased activity – N.D. Phloridzin, in vitro [74]
SLC34A2 downregulation A549 cells N.D. N.D. [53]





Reduced NFκB activation T47D, MDA-MB-231,
sarcoma cells
N.D. Bortezomib, in vitro [42, 43]
Reduced cell autophagy T47D, MDA-MB-231 cells N.D. Bortezomib, in vitro [43]
Decreased ERK1/2 phosphorylation T47D, MDA-MB-231 cells N.D. Bortezomib, in vitro [43]
Inhibition of p21, pRB dephosphorylation A375, T47D, Me180,
HBL100 cells
N.D. N.D. [32]
Increased ROS generation A375, T47D cells Increased sensitivity Antioxidants, in vitro [35, 39, 40]
Activation of AKT-PI3K RAT1 cells Increased sensitivity Antioxidants, in vitro [33]
p38α phosphorylation T47D cells, breast tumor Increased sensitivity Antioxidants, in vitro [39]
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